Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 9/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.41 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | EPHB3 | P54753 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | DRD4 | P21917 | 5/20 | 0.39 |
| ▸ | DRD3 | P35462 | 5/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13099745 | 0.92 | POLB (0.42) | FGFR1KDRFGFR4EPHB3 | |
| SCHEMBL8042730 | 0.90 | EGFR (0.41) | FGFR1KDRFGFR2EPHB3DRD2 | |
| SCHEMBL3234709 | 0.88 | FGFR4 (0.46) | FGFR4EPHB3 | |
| SCHEMBL13099744 | 0.86 | FGFR4 (0.43) | FGFR1KDRFGFR4EPHB3EGFR | |
| SCHEMBL8052018 | 0.86 | FGFR4 (0.48) | FGFR4EPHB3 | |
| SCHEMBL3242268 | 0.84 | FGFR4 (0.42) | FGFR1KDRFGFR4FGFR2EPHB3 | |
| SCHEMBL13099780 | 0.83 | WDR5 (0.42) | FGFR1KDRFGFR2DRD4KIT | |
| SCHEMBL8047356 | 0.82 | MAP4K1 (0.38) | FGFR1KDRHTR2A | |
| SCHEMBL8031078 | 0.82 | FGFR4 (0.41) | FGFR1KDRFGFR4EPHB3 | |
| SCHEMBL29923111 | 0.81 | FGFR1 (0.41) | FGFR1KDRFGFR4FGFR2EPHB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2010-10-07 | — | — | US | disclosed |
| WO-2009038385-A2 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHOONGWAE PHARMA CORPORATION (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256133-A1 | NOVEL COMPOUNDS HAVING INDAZOLE FRAMEWORKS, METHODS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | MAP3K20, MAP3K3, MAP3K1 | FGFR1 533/4885KDR 2436/4885FGFR4 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.